期刊文献+

不同方法制备可吸入乳糖颗粒的评价 被引量:1

Evaluation of Inhalable Lactose Particles Prepared by Different Methods
暂未订购
导出
摘要 目的筛选确定可吸入乳糖颗粒的制备方法和工艺。方法采用筛分法、研磨法、重结晶法、冷冻干燥法、喷雾干燥法制备乳糖颗粒,以所制得颗粒的粒径大小和形态以及含水量为主要评价指标,考察处方和工艺因素对颗粒特性的影响,筛选出可吸入颗粒的制备方法和工艺。结果采用优化的喷雾干燥法可获得平均粒径5.0μm以下的球形颗粒,适合于吸入给药;其他方法所获得颗粒平均粒径大、形状不规则,用于吸入给药需要进一步处理。结论喷雾干燥法的优化工艺可用于制备理想的可吸入颗粒。 Objective To select and establish a method and process of preparing inhalable particles.Methods The lactose particles were prepared by such methods as sieving,grinding,re-crystallization,freeze drying,spray drying.The particle size and morphology and water content were chosen as the main evaluation indexes to investigate the effect of formulation and process.Results The particles prepared by optimized spray drying process were spherical with an average particle size less than 5.0 μm,which were suitable for inhalation.All the other methods prepared irregular particles of a larger average size,which had to be further processed for inhalation.Conclusion The optimized spray drying method can be used for preparation of ideal inhalable particles.
出处 《解放军药学学报》 CAS 2012年第1期6-9,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
基金 "艾滋病和病毒性肝炎等重大传染病防治""十一五"科技重大专项资助 No.2008ZX10003-016 "重大新药创制""十一五"科技重大专项资助 No.2009ZX09301-002
关键词 可吸入颗粒 制备 喷雾干燥 inhalable particles preparation spray drying
  • 相关文献

参考文献12

  • 1Tamura G,Ohta K.Adherence to treatment by patients with asthma or COPD:Comparison between inhaled drugs and transdermal patch[J]. Respir Med,2007,101 (9):1895-1902.
  • 2Pilcer G,Amighi K.Formulation strategy and use of excipients in pulmonary drug delivery[J].Int J Pharm,2010,392(1-2):1-19.
  • 3Virchow JC,Crompton GK.Importance of inhaler devices in the management of airway disease[J].Respir Med,2008,102(1):10-19.
  • 4Shoyele SA,Slowey A.Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery[J].Int J Pharm,2006,314(1):1-8.
  • 5Siekmeier R,Scheuch G.Treatment of systemic diseases by inhalation of biomolecule aerosols[J].J Physiol Pharmacol,2009,60(5):15-26.
  • 6Suarez S,Hickey AJ.Drug properties affecting aerosol behavior[J].Respir Care,2000,45 (6):652-666.
  • 7Atkins PJ.Dry powder inhalers:an overview[J].Respir Care,2005,50 (10):1304-1312.
  • 8李凤前,胡晋红,朱全刚.干粉末吸入给药系统[J].国外医学(药学分册),2001,28(3):167-167. 被引量:16
  • 9赵磊磊,霍务贞,龚炜,朱盛山.吸入粉雾剂的研究进展[J].中国药学杂志,2006,41(20):1529-1532. 被引量:3
  • 10江荣高,王立青,王春龙,潘卫三.影响吸入粉雾剂分散性能的制剂因素[J].中国医药工业杂志,2006,37(1):50-53. 被引量:5

二级参考文献94

  • 1刘学武,李志义,夏远景,张晓冬.超临界反溶剂过程制备银杏叶提取物超细微粒[J].高校化学工程学报,2005,19(4):550-553. 被引量:15
  • 2张纪尧,沈志刚,陈建峰.水溶胶冻干法制备微粉化辛伐他汀[J].高校化学工程学报,2006,20(5):814-819. 被引量:9
  • 3Suarez S, Hickey A J. Drug properties affecting aerosol behavior [J]. Respiratory Care, 2000, 45(6): 652-666.
  • 4Timsina M P, Martin G E Marriott C et al. Drug delivery to the respiratory tract using dry powder inhalers [J]. Int J Pharm, 1994, 101(1-2): 1-13.
  • 5Steckel H, Thies J, Muller B W. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide [J]. Int J Pharm. 1997, 152(1): 99-110.
  • 6Lobo J M, Schiavone H, Palakodaty Set al. SCF-engineered powders for delivery of budesonide from passive DPI devices [J]. J Pharm Sci, 2005, 94(10): 2276-2288.
  • 7Velaga S E Berger R, Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide [J]. Pharm Res, 2002, 19(10): 1564-1571.
  • 8Ruch F, Matijevic E. Preparation of micrometer size budesonide particle by precipitation [J]. J Colloid Interf Sci, 2000, 229(1): 207-211.
  • 9Rasenack N, Steckel H, Mailer B W. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process [J]. J Pharm Sci, 2003, 92(1): 35-44.
  • 10Chen J F, Zhang J Y. Shen Z G et al. Production and characterization of amorphous cefuroxime axetil drug nanoparticles with novel technology: high-gravity antisolvent precipitation [J]. Ind & Eng Chem Res, 2006, 45(25): 8723-8727.

共引文献27

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部